Chrystal Louis
Net worth: - $ as of 30/08/2026
Net worth: - $ as of 30/08/2026
Dr. Chrystal U.
Louis was previously employed as a Chief Medical Officer by TScan Therapeutics, Inc., a Senior VP-Hematology Clinical Development by Zentalis Pharmaceuticals, Inc., a Vice President & Head-Medical Affairs by CRISPR Therapeutics, Inc., and an Executive Director-Myeloid Diseases by Celgene Corp.
She received her undergraduate degree from Southwestern University, a graduate degree from Tulane University School of Medicine and a doctorate degree from Tulane University School of Medicine.
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 30/03/2026 | 0 ( -.--% ) | - $ | 30/08/2026 |
| Companies | Position | End |
|---|---|---|
| TSCAN THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 01/09/2026 |
| ZENTALIS PHARMACEUTICALS, INC. | Corporate Officer/Principal | 29/02/2024 |
CRISPR Therapeutics, Inc.
CRISPR Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops gene based medicines for the treatment of human diseases | Corporate Officer/Principal | 31/10/2022 |
| CELGENE | Corporate Officer/Principal | 31/12/2018 |
Active
Inactive
Listed companies
Private companies
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
| Private companies | 6 |
|---|---|
Celgene Corp.
Celgene Corp. BiotechnologyHealth Technology Develops cancer and immunology drugs | Health Technology |
Southwestern University
Southwestern University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Tulane University School of Medicine
Tulane University School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
CRISPR Therapeutics, Inc.
CRISPR Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops gene based medicines for the treatment of human diseases | Health Technology |
TScan Therapeutics, Inc.
TScan Therapeutics, Inc. BiotechnologyHealth Technology Develops T-cell therapies for cancer patients | Health Technology |
Zentalis Pharmaceuticals, Inc.
Zentalis Pharmaceuticals, Inc. BiotechnologyHealth Technology Develops clinical therapeutics for targeting fundamental cancer pathways | Health Technology |
Select your edition
All financial news and data tailored to specific country editions